Tyvaso Dpi

  • Pulmonary hypertension

Tyvaso Dpi Generic Name & Formulations

General Description

Treprostinil 16mcg, 32mcg, 48mcg, 64mcg; per cartridge; dry pwd for inh.

Pharmacological Class

Prostacyclin analogue.

See Also

How Supplied

Ampules (2.9mL)—4; Starter Kit—1 (28 ampules with inhalation system); Refill Kit—1 (28 ampules with accessories); DPI Titration Kit—1 (112 cartridges [16mcg] + 84 cartridges [32mcg] w. 5 inhalers); (112 cartridges [16mcg] + 112 cartridges [32mcg] + 28 cartridges [48mcg] w. 5 inhalers); DPI Maintenance Kit—1 (112 cartridges [16mcg, 32mcg, 48mcg, or 64mcg] w. 5 inhalers); (112 cartridges [32mcg] + 112 cartridges [48mcg] w. 5 inhalers)

Generic Availability


Mechanism of Action

Treprostinil, a prostacyclin analogue, directly vasodilates pulmonary and systemic arterial vascular beds and inhibits platelet aggregation.

Tyvaso Dpi Indications


To improve exercise ability in patients with: pulmonary arterial hypertension (WHO Group 1) with NYHA Class III symptoms; and pulmonary hypertension associated with interstitial lung disease (WHO Group 3).

Tyvaso Dpi Dosage and Administration


Give 4 separate, equally spaced treatment sessions each day approximately 4hrs apart, during waking hours. ≥18yrs: Initially 16mcg per treatment session. Maintenance: increase by 16mcg per session at approximately 1–2 week intervals; target dose usually: 48–64mcg per session. Dosage for transition from Tyvaso Inhalation Solution: see full labeling.


<18yrs: not established.

Tyvaso Dpi Contraindications

Not Applicable

Tyvaso Dpi Boxed Warnings

Not Applicable

Tyvaso Dpi Warnings/Precautions


Risk of symptomatic hypotension in those with low systemic arterial pressure. Hepatic insufficiency; titrate slowly. Risk of bleeding. Asthma, COPD, or other bronchial hyperreactivity. For Tyvaso Inhalation Solution: avoid contact with eyes and skin, oral ingestion. Elderly. Pregnancy. Nursing mothers.

Tyvaso Dpi Pharmacokinetics


Hepatic (CYP2C8). 91% plasma protein bound.


Renal (79%), fecal (13%). Half-life: ~4 hours (Tyvaso Inhalation Solution); 27–50 minutes (Tyvaso DPI).

Tyvaso Dpi Interactions


Do not use with other medications. May be potentiated by CYP2C8 inhibitor (eg, gemfibrozil). May be antagonized by CYP2C8 inducer (eg, rifampin).

Tyvaso Dpi Adverse Reactions

Adverse Reactions

Cough, headache, nausea, diarrhea, dizziness, flushing, throat irritation, pharyngolaryngeal pain, syncope, dyspnea; symptomatic hypotension, bleeding, bronchospasm.

Tyvaso Dpi Clinical Trials

See Literature

Tyvaso Dpi Note

Not Applicable

Tyvaso Dpi Patient Counseling

See Literature